Specialized care for cervical, endometrial, and ovarian cancers — combining minimally invasive and fertility-preserving surgery with comprehensive systemic therapy, led by renowned experts from Peking Union Medical College Hospital.
Comprehensive gynecologic cancer care that addresses the full spectrum of women's cancers, with a commitment to both cancer eradication and quality of life.
The Gynecologic Oncology Center at Beijing Arion Cancer Hospital provides specialized care for cervical cancer, endometrial cancer, and ovarian cancer — the three most common gynecologic malignancies. Our center combines surgical expertise, advanced systemic therapy, and precision radiation oncology within a coordinated MDT framework.
Our MDT team integrates gynecologic oncology surgery, medical oncology, and radiation oncology to develop individualized treatment plans for each patient. For early-stage cancers, we prioritize minimally invasive surgical approaches and fertility-preserving options for women who wish to retain their reproductive potential. For advanced cases, we deploy comprehensive systemic therapy including chemotherapy, targeted therapy, and immunotherapy.
What sets our center apart is the leadership of specialists from Peking Union Medical College Hospital (PUMCH) — China's most prestigious medical institution. This expertise, combined with our UPMC partnership and real-time MDT model, ensures that patients receive internationally standardized care with the compassion and dignity that gynecologic cancer patients deserve.
Curing cancer while preserving fertility and quality of life
Our center provides comprehensive care for the full range of gynecologic malignancies.
From HPV-related precancerous lesions to invasive cervical cancer. We offer HPV testing, colposcopy, cone biopsy for early lesions, radical hysterectomy for invasive disease, and chemoradiation for locally advanced cases. Fertility-preserving trachelectomy is available for selected early-stage patients.
The most common gynecologic malignancy. We provide comprehensive care from diagnostic hysteroscopy and D&C to minimally invasive hysterectomy, lymph node staging, and adjuvant therapy. Fertility-preserving hormonal therapy is offered for selected young patients with early-stage, low-grade disease.
The most lethal gynecologic malignancy. Our MDT team provides comprehensive care including cytoreductive surgery, neoadjuvant chemotherapy, maintenance therapy with PARP inhibitors and anti-angiogenic agents, and genetic testing for BRCA mutations to guide treatment and assess hereditary risk.
Three core specialties working as one team to ensure coordinated, personalized care for every gynecologic cancer patient.
Our gynecologic oncologic surgeons perform minimally invasive (laparoscopic and robotic) and open surgical procedures tailored to cancer type and stage. Procedures include radical hysterectomy, ovarian cancer cytoreduction, fertility-preserving surgery, and sentinel lymph node mapping — all planned within the MDT framework.
Systemic therapy is tailored to the specific cancer type, molecular profile, and patient circumstances. This includes neoadjuvant and adjuvant chemotherapy, targeted therapy (anti-angiogenic agents, PARP inhibitors), immunotherapy for MSI-high or PD-L1 positive tumors, and hormonal therapy for selected endometrial cancers.
Radiation therapy plays a central role in cervical cancer treatment and is used selectively for endometrial and other gynecologic cancers. We offer external beam radiation therapy (EBRT) with IMRT for precise targeting, and brachytherapy for intracavitary treatment — often combined with concurrent chemotherapy for locally advanced cervical cancer.
A full range of gynecologic cancer treatments, individually tailored and MDT-coordinated.
Laparoscopic and robotic-assisted surgery for cervical, endometrial, and ovarian cancers. Smaller incisions, reduced blood loss, shorter hospital stay, and faster recovery compared to traditional open surgery — without compromising oncologic outcomes.
For young women with early-stage gynecologic cancer who wish to preserve fertility, we offer fertility-sparing procedures including radical trachelectomy for cervical cancer, hormonal therapy for early endometrial cancer, and fertility-sparing ovarian surgery — carefully selected based on cancer type and stage.
Evidence-based chemotherapy regimens for neoadjuvant, adjuvant, and palliative settings. Platinum-based combinations for ovarian cancer, taxane-platinum doublets, and other protocols tailored to cancer type, stage, and patient condition.
Precision targeted therapy including PARP inhibitors (olaparib, niraparib) for BRCA-mutated ovarian cancer, anti-angiogenic agents (bevacizumab), and other molecularly targeted drugs guided by comprehensive genomic profiling of the tumor.
Immune checkpoint inhibitors for MSI-high, dMMR, or PD-L1 positive gynecologic cancers. Used as monotherapy or in combination with other treatments, offering new hope for patients with advanced or recurrent disease.
BRCA1/BRCA2 genetic testing and hereditary cancer risk assessment for patients and their families. Genetic counseling guides preventive strategies for at-risk relatives and informs treatment decisions for PARP inhibitor eligibility.
Our center is led by a renowned gynecologic oncologist from Peking Union Medical College Hospital — China's most prestigious medical institution.
A renowned gynecologic oncology surgeon from Peking Union Medical College Hospital (PUMCH) — China's most prestigious medical institution. Dr. Wu is widely recognized as one of China's leading gynecologic oncologists, with decades of surgical experience treating cervical, endometrial, and ovarian cancers. He is known for his expertise in complex gynecologic cancer surgery, his commitment to advancing surgical techniques, and his dedication to training the next generation of gynecologic oncologists. His leadership brings PUMCH-level excellence to the Arion Gynecologic Oncology Center.
Our unique advantages make us a trusted destination for women seeking expert gynecologic cancer treatment in China.
Our center is led by Dr. Wu Ming from Peking Union Medical College Hospital — bringing the surgical expertise and clinical excellence of China's top medical institution to every patient's treatment plan.
We understand that many gynecologic cancer patients are young women who hope to have children. Our MDT team carefully evaluates fertility-preserving options for eligible patients, balancing cancer treatment with future reproductive potential.
Gynecologic cancer care requires sensitivity and respect. Our international patient team provides a comfortable, private environment with female staff available, multilingual support, and a dedicated Case Manager who understands the unique needs of women navigating cancer treatment.